Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $31.00 at B. Riley Financial

Trevi Therapeutics (NASDAQ:TRVI) had its price objective upped by B. Riley Financial from $21.00 to $31.00 in a research report report published on Monday, MarketBeat.com reports. They currently have a buy rating on the stock.

Several other research firms also recently commented on TRVI. Wall Street Zen upgraded Trevi Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Friday. Stifel Nicolaus set a $30.00 price objective on Trevi Therapeutics in a research note on Friday, May 8th. Morgan Stanley reissued an “overweight” rating and set a $20.00 price objective on shares of Trevi Therapeutics in a report on Wednesday, May 6th. Finally, D. Boral Capital reissued a “buy” rating and set a $19.00 price objective on shares of Trevi Therapeutics in a report on Friday, April 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $24.91.

Trevi Therapeutics Stock Down 12.1%

Shares of TRVI opened at $16.77 on Monday. The stock has a market cap of $2.38 billion, a price-to-earnings ratio of -52.41 and a beta of 1.00. Trevi Therapeutics has a 12 month low of $6.55 and a 12 month high of $20.22. The company has a 50-day moving average price of $15.89 and a two-hundred day moving average price of $13.36.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). Equities research analysts expect that Trevi Therapeutics will post -0.47 EPS for the current fiscal year.

Institutional Trading of Trevi Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hilton Head Capital Partners LLC raised its position in shares of Trevi Therapeutics by 32.6% in the 1st quarter. Hilton Head Capital Partners LLC now owns 4,250 shares of the company’s stock valued at $51,000 after acquiring an additional 1,044 shares during the period. AlphaCentric Advisors LLC boosted its stake in Trevi Therapeutics by 5.7% during the 1st quarter. AlphaCentric Advisors LLC now owns 23,970 shares of the company’s stock worth $286,000 after acquiring an additional 1,303 shares during the last quarter. Kennedy Capital Management LLC grew its holdings in Trevi Therapeutics by 2.4% during the fourth quarter. Kennedy Capital Management LLC now owns 56,269 shares of the company’s stock valued at $704,000 after purchasing an additional 1,336 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Trevi Therapeutics by 32.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company’s stock valued at $78,000 after purchasing an additional 1,523 shares during the period. Finally, Oppenheimer & Co. Inc. increased its stake in Trevi Therapeutics by 2.1% in the fourth quarter. Oppenheimer & Co. Inc. now owns 100,698 shares of the company’s stock valued at $1,261,000 after purchasing an additional 2,030 shares in the last quarter. 95.76% of the stock is currently owned by institutional investors and hedge funds.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.